| Today’s Big NewsFeb 28, 2024 |
|
Thursday, March 7, 2024 | 1pm ET / 10am PT Join us for this timely look at the critical role a CDMO’s process development approach can play in shortening development timelines for biotherapeutics. Gain key insights on risk-mitigation strategies, utilizing flexible development platforms, optimizing integration, managing process development, and more. Register now. |
|
| By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
|
|
|
By Kevin Dunleavy The first 12 months on the market for Apellis’ geographic atrophy (GA) drug Syfovre have been a rollercoaster ride. And there are still more loops to negotiate. On Tuesday, when Apellis presented its quarterly earnings, its report raised more questions about Syfovre than it answered. |
By Conor Hale The spending spree comes alongside Ginkgo’s unveiling of a new technology network that encompasses a list of offerings from more than 25 of the company’s developer partners and previous acquisitions. |
By Max Bayer With the stage set for the first psychedelic-based therapy to nab FDA approval this year, even J.P. Morgan can't resist the allure of compelling data and wide-open markets. |
|
Thursday, March 7, 2024 | 2pm ET / 11am PT Join us for this discussion on the future of cloud computing in healthcare. Learn key insights on the investments being made to advance research and commercial efforts. We will explore topics such as data sharing without data movement, the future of analytics and privacy, the use of ML models for lookalike audiences supported by cloud computing, and more. Register now. 
|
|
By Ben Adams What do comedian and actress Amy Schumer and the British monarch King Charles III have in common? |
By Andrea Park The FDA put out a safety communication Tuesday warning about the possibility of “serious complications” tied to the use of Hologic’s BioZorb devices. |
By Zoey Becker After an initial FDA approval came later than anticipated, UCB is looking to quickly grow Bimzelx. The company is eying four new indications and potential peak sales of 4 billion euros. |
By Gabrielle Masson After being the center of speculation for several months, Cytokinetics’ CEO Robert Blum is putting the kibosh on the rumor that Novartis will be acquiring the biotech. |
By Andrea Park Fresh off earning an updated FDA clearance for its flagship neuromodulation device, Mainstay Medical has closed an equity financing round to help expand the device’s global presence. |
By Fraiser Kansteiner On the back of its $350 million deal for two late-stage Idorsia assets, Viatris will continue to be “opportunistic” when it comes to making future business development grabs—especially on the commercial side—executives said Wednesday. |
By Nick Paul Taylor Idorsia has survived a high-wire financing act. Weeks from the end of its cash runway, the biotech has secured $350 million upfront from Viatris in exchange for the global rights to two phase 3 candidates. |
By Angus Liu The FDA has cleared Rovi's active substance manufacturing plant in Granada, Spain, to churn out Moderna's COVID vaccine for the U.S. market. Meanwhile, Rovi CEO Juan López-Belmonte sees the Novo-Catalent M&A deal as a “tremendous opportunity” for his company. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Editor-in-Chief Ayla Ellison explores the critical issue of maternal mental health in an interview with Dr. Ken Levey, co-founder and CEO of Mother Goose Health. |
|
|---|
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
